Chronic renal diseases with highly enhanced glomerular permeability to proteins are accompanied by tubulointerstitial inflammation and scarring and progression to renal failure. As a consequence of increased glomerular permeability, proteins filtered through the glomerular capillary in excessive amount have intrinsic renal toxicity at least partially linked to their accumulation in the proximal tubular cell cytoplasm during the process of reabsorption along the nephron. Experimental evidence is available showing that protein overload per se activates proximal tubular epithelial cells in culture to upregulate genes encoding for endothelin, chemokines and cytokines. These vasoactive and inflammatory substances, formed in excessive quantities by the tubular cells, are released mainly into the basolateral compartment, a pattern of secretion that in the kidney would favor recruitment and activation of inflammatory cells into the renal interstitium and fibrogenic reaction leading to renal scarring.

Keywords:
Protein traffic, Interstitial inflammation, Endothelin, Chemokines, Progressive renal disease
1.
Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652–659.
2.
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85–F93.
3.
Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA: Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int 1982;22:112–126.
4.
Wen S-F, Huang T-P, Moorthy AV: Effect of low-protein diet on experimental diabetic nephropathy in the rat. J Lab Clin Med 1985;106:589–597.
5.
Hosetter TH, Meyer TW, Rennke HG, Brenner BM: Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 1986;30:509–517.
6.
Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612–619.
7.
Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993–2000.
8.
Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925–1930.
9.
Anderson S, Rennke HG, Garcia DL, Brenner BM: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526–536.
10.
Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384–394.
11.
Deen WM, Bridges CR, Brenner BM, Myers BD: Heteroporous model of glomerular size selectivity: Application to normal and nephrotic humans. Am J Physiol 1985;249:F374–F389.
12.
Remuzzi A, Battaglia C, Rossi L, Zoja C, Remuzzi G: Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. Am J Physiol 1987;253:F318–F327.
13.
Yoshioka T, Mitarai T, Kon V, Deen WM, Rennke HG, Ichikawa I: Role for angiotensin II in an overt functional proteinuria. Kidney Int 1986;30:538–545.
14.
Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I: Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: A study in early passive Heymann nephritis. Circ Res 1987;61:531–538.
15.
Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997;51:2–15.
16.
Schwegler JS, Heppelmann B, Mildenberger S, Silbernagl S: Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: A model for proximal tubular protein reabsorption. Pflügers Arch 1991;418:383–392.
17.
Wall DA, Maack T: Endocytic uptake, transport, and catabolism of proteins by epithelial cells. Am J Physiol 1985;248:C12–C20.
18.
Maack T, Park CH, Camargo MJF: Renal filtration, transport, and metabolism of proteins; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology. New York, Raven Press, 1985, pp 1773–1803.
19.
Maack T: Changes in the activity of acid hydrolases during renal reabsorption of lysozyme. J Cell Biol 1967;35:268–273.
20.
Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994;5:1273–1287.
21.
Bertani T, Zoja C, Abbate M, Rossini M, Remuzzi G: Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. Lab Invest 1989;60:196–204.
22.
Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G: Tubulointerstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986;30:488–496.
23.
Davies DJ, Brewer DB, Hardwicke J: Urinary proteins and glomerular morphometry in protein overload proteinuria. Lab Invest 1978;38:232–243.
24.
Weening JJ, Van Guldener C, Daha MR, Klar N, Van Der Wal A, Prins FA: The pathophysiology of protein-overload proteinuria. Am J Pathol 1987;129:64–73.
25.
Eddy AA, McCulloch L, Adams J, Liu E: Interstitial nephritis induced by protein overload proteinuria. Am J Pathol 1989;135:719–733.
26.
Mori H, Yamashita H, Nakanishi C, Koizumi K, Makino S, Kishimoto Y, Hayashi Y: Proteinuria induced by transplantable rat pituitary tumor MtT SA5. Model for homologous protein overload proteinuria. Lab Invest 1986;54:636–644.
27.
Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998;9:1213–1224.
28.
Park CH, Maack T: Albumin absorption and catabolism by isolated perfused proximal convoluted tubules of the rabbit. J Clin Invest 1984;73:767.
29.
Brunskill NJ, Cockcroft N, Nahorski S, Walls J: Albumin endocytosis is regulated by heterotrimeric GTP-binding protein Gαi-3 in opossum kidney cells. Am J Physiol 1996;271:F356–F364.
30.
Gekle M, Mildenberger S, Freudinger R, Schwerdt G, Silbernagl S: Albumin endocytosis in OK cells: Dependence on actin and microtubules and regulation by protein kinases. Am J Physiol 1997;272:F668–F677.
31.
Gekle M, Mildenberger S, Freudinger R, Silbernagl S: Long-term protein exposure reduces albumin binding and uptake in proximal tubule-derived opossum kidney cells. J Am Soc Nephrol 1998;9:960–968.
32.
Cessac-Guillemet AL, Mounier F, Borot C, et al: Characterization and distribution of albumin binding protein in normal rat kidney. Am J Physiol 1996;271:F101–F107.
33.
Cui S, Verroust PJ, Moestrup SK, Christensen EI: Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996;271:F900–F907.
34.
Haymann J-P, Bouet S, Levraud J-P, et al: Characterization of the neonatal Fc receptor (FcRn) on cultured human glomerular epithelial cells. Localization of FcRn in normal human kidney (abstract). J Am Soc Nephrol 1997;8:456.
35.
Olbricht CJ, Cannon JK, Garg LC, Tisher CC: Activities of cathepsin B and L in isolated nephron segments from proteinuric and non proteinuric rats. Am J Physiol 1986;250:F1055–F1062.
36.
Zager RA, Schimpf BA, Bredl CR, Gmur DJ: Inorganic iron effects on in vitro hypoxic proximal tubular cell injury. J Clin Invest 1993;91:702–708.
37.
Chen L, Boadle RA, Harris DCH: Toxicity of holotransferrin but not albumin in proximal tubule cells in primary culture. J Am Soc Nephrol 1998;9:77–84.
38.
Alfrey AC, Froment DH, Hammond WS: Role of iron in tubulointerstitial injury in nephrotoxic serum nephritis. Kidney Int 1989;36:753–759.
39.
Howard RL, Buddington B, Alfrey AC: Urinary albumin excretion, transferrin and iron excretion in diabetic patients. Kidney Int 1991;40:923–926.
40.
Hirschberg R: Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions. J Clin Invest 1997;98:116–124.
41.
Nomura A, Morita Y, Maruyama S, et al: Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol 1997;151:539–547.
42.
Biancone L, David S, Della Pietra V, Montrucchio G, Cambi V, Camussi G: Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int 1994;45:451–460.
43.
David S, Biancone L, Caserta C, Bussolati B, Cambi V, Camussi G: Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol Dial Transplant 1997;12:51–56.
44.
Remuzzi G: Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 1995;4:339–342.
45.
Remuzzi G, Benigni A: Endothelins in the control of cardiovascular and renal function. Lancet 1993;342:589–593.
46.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;322:411–415.
47.
Kohan DE: Endothelin synthesis by rabbit renal tubule cells. Am J Physiol 1991;261:F221–F226.
48.
Kohan DE, Padilla E: Endothelin-1 is an autocrine factor in rat inner medullary collecting ducts. Am J Physiol 1992;32:F607–F612.
49.
Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco PM, Remuzzi G: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934–941.
50.
Fish EM, Molitoris BA: Alteration in epithelial polarity and the pathogenesis of disease states. N Engl J Med 1994;330:1580–1588.
51.
Ong ACM, Jowett TP, Firth JD, Burton S, Kitamura M, Fine LG: A new paracrine loop implicated in human tubulo-interstitial fibrosis: Tubular-derived endothelins modulate renal interstitial fibroblast function (abstract). J Am Soc Nephrol 1993;4:473.
52.
Achmad TH, Rao GS: Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 1992;189:994–1000.
53.
Ong AC, Jowett TP, Moorhead JF, Owen JS: Human high density lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells. Kidney Int 1994;46:1315–1321.
54.
Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440–444.
55.
Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481–489.
56.
Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354–358.
57.
Zoja C, Corna D, Bruzzi I, Foglieni C, Bertani T, Remuzzi G, Benigni A: Passive Heymann nephritis: Evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Nephrol 1996;4:213–221.
58.
Theuring F, Schmager F, Thone-Reinecke CE, et al: Transgenic mice in endothelin research (abstract). 4th Int Conf on Endothelin, London, 1995, p 146.
59.
Hocher B, Liefeldt L, Thone-Reineke C, et al: Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 1996;28:196–201.
60.
Takeda M, Komeyama T, Tsutsui T, Mizusawa T, Katayama Y, Go H, Tamaki M, Hatano A: Changes in urinary excretion of endothelin-1 like immunoreactivity before and after unilateral nephrectomy in humans. Comparison with other urinary parameters and unilateral adrenalectomy. Nephron 1994;67:180–184.
61.
Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, Marumo F: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991;39:307–311.
62.
Zoja C, Liu X-H, Abbate M, Corna D, Schiffrin EL, Remuzzi G, Benigni A: Angiotensin II blockade limits tubular protein overreabsorption and the consequent up-regulation of endothelin 1 gene in experimental membranous nephropathy. Exp Nephrol 1998;6:121–131.
63.
Bruzzi I, Corna D, Zoja C, Orisio S, Schiffrin EL, Cavallotti D, Remuzzi G, Benigni A: Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am J Pathol 1997;151:1241–1247.
64.
Schreiner GF: Renal toxicity of albumin and other lipoproteins. Curr Opin Nephrol Hyperten 1995;4:369–373.
65.
Kees-Folts D, Sadow JL, Schreiner GF: Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 1994;45:1697–1709.
66.
Luckow B, Schlöndorff D: The monocyte chemoattractant protein 1; in Schlöndorff D, Bonventre JV (eds): Molecular Nephrology. Kidney Function in Health and Disease. New York, Dekker, 1995, pp 653–671.
67.
Wang Y, Chen J, Chen L, Tay Y-C, Rangan GK, Harris DCH: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997;8:1537–1545.
68.
Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546–1557.
69.
Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K: Properties of the novel proinflammatory supergene ‘intercrine’ cytokine family. Annu Rev Immunol 1991;9:617–648.
70.
Schall TJ, Bacon K, Toy KJ, Goeddel DV: Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669–671.
71.
Wolf G, Luckow B, Schlöndorff D: Molecular biology and function of the chemoattractant cytokines RANTES and CSF-1; in Schöndorff D, Bonventre JV (eds): Molecular Nephrology. Kidney Function in Health and Disease. New York, Dekker, 1995, pp 673–679.
72.
Heeger P, Wolf G, Meyers C, Sun MJ, O’Farrell SC, Krensky AM, Neilson EG: Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes. Kidney Int 1992;41:220–225.
73.
Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kB activation. Kidney Int 1998;53:1608–1615.
74.
Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TNC, Salant DJ, Gutierrez-Ramos J-C: RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997;185:1371–1380.
75.
Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, Sawamoto S, Ishigatsubo Y, Okubo T: NF-kB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994;153:2052–2063.
76.
Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM: Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 1993;151:2601–2612.
77.
Baeuerle PA, Henkel T: Function and activation of NF-kB in the immune system. Annu Rev Immunol 1994;12:141–179.
78.
Baldwin AS: The NF-kB and IkB proteins: New discoveries and insights. Annu Rev Immunol 1996;14:649–681.
79.
Barnes PJ, Karin M: Nuclear factor-kB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;356:1066–1071.
80.
Pahl HL, Baeuerle PA: A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kB. EMBO J 1995;14:2580–2588.
81.
Donadelli R, Zoja C, Benigni A, Bruzzi I, Abbate M, Balducci D, Zanchi C, Remuzzi G: ACE inhibition while reducing proteinuria also suppresses NF-kB activation and reduces renal MCP-1 in rats with remnant kidney (abstract). J Am Soc Nephrol 1998;9:453A.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.